



## Company Announcement

### Nykode Therapeutics reports full year 2021 financial results

Management to host webcast on April 1, 2022, at 11.30 a.m. CET / 5.30 a.m. ET

Oslo, Norway, March 31, 2022 – Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced that the Board of Directors has approved the Company's financial statements for 2021.

"2021 was another year of significant progress for Nykode," said Michael Engsig, Chief Executive Officer of Nykode Therapeutics. "We launched our new company name and brand identity, a first step in our journey to become a leading global immunotherapy company. We signed two transformative research licensing agreements with Adaptive Biotechnologies and Regeneron, which will accelerate the development of our technology platform across multiple areas of high unmet need. In addition, we made substantial progress in the development of our oncology and infectious disease pipelines, including dosing the first subjects in our Phase I/II clinical trial of Nykode's next-generation SARS-CoV-2 vaccine candidates. Furthermore, we expanded and evolved the organization to over 100 employees, adding new valuable skills and capabilities to our team. We believe Nykode is well-positioned to continue to execute on our world-class collaborations and advance our technology platform and clinical programs, and we look forward to sharing updates this year."

#### Highlights for 2021

- March - Adopted IFRS (International Financial Reporting Standards) and announced initiative to explore a potential listing of its shares on the Nasdaq Global Market in the US
- March – Nykode's first IND was opened in the VB10.NEO program
- June - Initiated a Phase I/II trial to evaluate two next-generation SARS-CoV-2 virus DNA vaccine candidates to address emerging variants of concern
- July - Entered into worldwide in-licensing agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in next-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of concern
- November - First subject dosed in Phase I/II clinical trial with next-generation SARS-CoV-2 vaccine candidates
- November - Nykode announced a change of company name from Vaccibody to Nykode Therapeutics



- November - Entered into multi-target license and collaboration agreement with Regeneron
- December - Announced first subject dosed with its T cell-focused next-generation SARS-CoV-2 vaccine candidate

### **Full year 2021 key figures**

- Total operating income of USD 35.8 million in 2021, compared to USD 215.7 million in 2020
- Total operating expenses of USD 46.5 million in 2021, compared to USD 37.4 million in 2020
- Net loss of USD 9.4 million in 2021, compared to a net profit of USD 149.8 million in 2020
- Cash and cash equivalents of USD 216.2 million at year-end 2021, compared to USD 183.9 million at year-end 2020
- Other current financial assets of USD 12.2 million at year-end 2021, compared to USD 24.9 million at year-end 2020
- Total equity of USD 194.1 million at year-end 2021, compared to USD 178.9 million at year-end 2020
- Total assets of USD 265.6 million at year-end 2021, compared to USD 230.0 million at year-end 2020

---

The Company's annual accounts for the financial year 2021, including the financial statements and annual report, are together with the auditor's report attached to this announcement.

Investors and analysts are invited to join a webcast presentation of the 2021 financial results conducted by CEO Michael Engsig and other members of management April 1, 2022, at 11.30 a.m. CET / 5.30 a.m. ET.

An updated corporate presentation will be available in the Investors section of the Company's website at 7:00 a.m. CET on April 1 at [www.nykode.com/investors](http://www.nykode.com/investors). The live and archived webcast of the presentation can be accessed in the Investors section of the Company's website [here](#).

### **About Nykode Therapeutics**

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and eliciting efficacious clinical responses.



Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.

The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Nykode Therapeutics' shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is NYKD. Further information about Nykode Therapeutics may be found at <http://www.nykode.com>.

**Contact for Nykode Therapeutics AS:**

CEO Michael Engsig  
Nykode Therapeutics AS  
[IR@nykode.com](mailto:IR@nykode.com)

**Nykode Therapeutics AS**

Oslo Science Park  
Gaustadalléen 21  
N-0349 Oslo, Norway

**Forward-looking statements for Nykode Therapeutics**

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.